Signs Point to Warren Buffett's Successor, Greg Abel, Dumping the Oracle of Omaha's Former No. 2 Holding at Berkshire Hathaway

Bank of America may be losing its status as a Berkshire Hathaway core holding after Buffett and Greg Abel omitted it from their 'indefinite' / 'compound over decades' lists. Berkshire has cut its BofA stake for six straight quarters, trimming about 515.6 million shares, or roughly 50%, from a 1.03 billion-share position. The stock also no longer screens as a deep value play, trading at a 43% premium to book value versus a 62% discount in 2011.

Analysis

The key market signal is not simply a succession change; it is a regime shift in capital allocation style. Berkshire under Abel is likely to behave more like an institutional compounder with tighter hurdle rates, which makes legacy large-bank exposure less defensible when the upside is capped and the balance sheet is not being bought at distress pricing. That matters because the marginal buyer for mega-cap financials has been valuation-insensitive index flows; if Berkshire is no longer a structural holder, BAC loses a high-credibility anchor and the stock’s multiple can compress faster than fundamentals would justify.

Second-order, the unwinding of a concentrated financial stake can ripple through the sector. If BAC is being sold for valuation and rate-sensitivity reasons, peers with similar deposit beta/asset-sensitivity profiles can see the market extrapolate a broader "peak NII, lower multiple" regime, even if their fundamentals differ. By contrast, holdings explicitly framed as long-duration compounds or capital-return machines should benefit from a relative scarcity premium: the market will likely reward names that fit Abel’s narrower definition of durable compounding, especially where buybacks can absorb float and offset a slower macro backdrop.

The contrarian read is that the selloff rationale may be partially backward-looking. If rate cuts remain delayed or shallow, BAC’s NII pressure is less severe than the market may fear, and the stock’s premium to book is still not excessive versus high-quality banks with stronger fee mixes. But the bigger issue is opportunity cost: in a market where Berkshire can redeploy into simpler compounding stories, BAC needs to clear a much higher bar. That makes any near-term bounce vulnerable unless management can prove durable ROE expansion or materially faster buyback execution.

Catalyst timing matters. In the next 1-2 13F cycles, continued trimming would force systematic holders to re-underwrite the position as a non-core asset, which is more damaging to sentiment than the raw share count reduction. Conversely, a cessation of sales would be a meaningful positive surprise, but absent that, the path of least resistance is continued derating versus money-center peers with cleaner capital-return narratives.

Key Decisions for Investors

• Short BAC vs long AXP or MCO over 1-3 months; the pair isolates the market’s reward for durable compounding and capital-light fee streams versus balance-sheet-heavy financials. Target ~8-12% relative downside if Berkshire-style de-rating spreads to BAC.
• If holding BAC, buy downside protection via 3-6 month put spreads rather than naked longs; the thesis is sentiment/ownership overhang, not immediate solvency risk. Favor strikes around 5-10% below spot to finance theta.
• Add to BRK.B on any post-succession weakness only if the portfolio rotates toward higher-conviction compounders; otherwise treat it as a neutral-to-slight short against quality conglomerates with clearer capital deployment. Risk/reward improves if the market over-discounts succession noise.
• Rotate financial exposure from BAC into capital-return-heavy banks or insurers with lower rate sensitivity and more visible buyback capacity. The trade works best over 6-12 months if the market keeps pricing a slower NII growth path.
• Avoid chasing BAC rallies unless 13F data shows sales have stopped; absent that confirmation, rallies are likely sellable into a 2-4 week window.